Horwitz SM, et al. - In this work, the final ALCANZA results were reported (data cut-off: September 28, 2018; median follow-up for overall survival: 45.9 months). As per original ALCANZA analysis (median follow-up: 22.9 months), brentuximab vedotin (BV) vs physician's choice (PC) (methotrexate or bexarotene) for the treatment of CD30+ CTCL led to significant improvements in the rate of objective response lasting ≥4 months (ORR4) and progression-free survival (PFS). Adults with previously treated CD30+ mycosis fungoides (including transformed MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) were randomly administered either BV or PC. One hundred and twenty-eight patients comprised the intent-to-treat population. Final analyses from ALCANZA establish that BV vs PC in CD30+ CTCL results in better, durable responses and longer PFS. Compared to PC, BV manifested extended time to next therapy. This implies clinically meaningful durable BV responses. Twenty-seven percent of patients treated with BV exhibited peripheral neuropathy, but all grade 1/2.